Search Results 881-890 of 16407 for monoclonal antibody

1. Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) - Mayo Clinic

   Prior monoclonal antibody within 4 weeks prior to study Day 1 (2 weeks for RS participants) or who has not recovered (i.e. ≤ Grade 1 or at baseline) from ...

2. Development of Potential COVID-19 Vaccine and Serological Assay - Mayo Clinic

   Our group has explored the use of genomic RNA/phage display libraries derived from primary human malignant melanoma cells as a means of identifying antibody ...

3. Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) - Mayo Clinic

   ... monoclonal antibodies (Grade ≥ 3 National Cancer Institute [NCI]-Common ... antibody, or anti-4-1BB antibody is not allowed, inclusive of localized ...

4. The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis - Mayo Clinic

   History of Grade ≥ 3 infusion-associated AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine or acetaminophen ...

5. Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer - Mayo Clinic

   composition to nivolumab (Parts A+ B) and/or ipilimumab (Part B) - History of severe hypersensitivity reaction to any monoclonal antibody - Uncontrolled ...

6. Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

   Have a history of allergic reaction to prior monoclonal antibody or biologic agent Have received previous treatment with MORAb-004 (anti-TEM-1); Have a ...

7. A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia - Mayo Clinic

   Received an anti-CLL monoclonal antibody within 8 weeks prior to the first dose of study drug. Received any anti-cancer or investigational therapy within 14 ...

8. A Study of Atezolizumab Alone or Combined with Immunomodulatory Drug and/or Daratumumab in Multiple Myeloma Patients - Mayo Clinic

   Receipt of ≥ 2 prior lines of therapy and progressed on treatment with an anti-CD38 monoclonal antibody (Cohort D3). Receipt of ≥ 4 lines of prior therapy ...

9. A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid) - Mayo Clinic

   A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody- ...

10. Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) - Mayo Clinic

    Has had prior anti-cancer monoclonal antibody within 4 weeks of Study Day 1 or who has not recovered from adverse events due to agents administered >4 weeks ...